Project Grant HT94252510570
Award Date
9/1/25
Completion Date
8/31/28
Dollars Obligated
$480K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This federal Project Grant award of $720,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by Baylor College of Medicine to investigate "Targeting Cryptic Splicing-Derived Neoantigens in HNRNPM-Dysregulated Triple-Negative Breast Cancer". The research aims to transform healthcare for military service members, veterans, and the public by advancing innovative biomedical research across diverse medical domains. Baylor...
The federal Project Grant award provides $1,151,250.00 to Texas A&M University System Health Science Center to develop a unique small molecule for triple-negative breast cancer. The grant is funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the public. The award period runs from July 1, 2024 to June 30, 2027....
This federal Project Grant award of $505,071.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by The University of Texas M.D. Anderson Cancer Center to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The award period runs from February 15, 2025 to February 14, 2028. The Military Medical Research and Development program funds diverse biomedical research...
The federal Project Grant award of $718,858.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The award was granted to The University of Texas M.D. Anderson Cancer Center on February 15, 2025, with a planned completion date of February 14, 2028. As a leading academic cancer research institution, M.D....
This federal Project Grant award of $2,542,500.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research aimed at therapeutically targeting the tumor microenvironment in triple-negative breast cancer patients at high risk of relapse, as well as preclinical models of lung metastases. The award was granted to the Weill Medical College of Cornell University, a prestigious academic medical institution, with a performance...
This $1,600,000.00 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research at Baylor College of Medicine focused on developing new synthetic lethal combination therapies targeting TopBP1 and the arachidonic acid pathway for breast cancer treatment. The three-year award, with an end date of February 28, 2027, will fund basic, translational, and clinical research aimed at advancing scientific understanding and...
This $871,016 Project Grant awarded on January 1, 2024 by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to the Beckman Research Institute of the City of Hope supports research on a highly tumor-specific oncolytic virus combined with a viral protein-target T cell engager for the treatment of triple-negative breast cancer. The grant aims to develop innovative therapies for this aggressive form of breast cancer that impacts military personnel and veterans. As a...
The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...
The federal Project Grant award of $5,471,258.00 from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to The University of Texas M.D. Anderson Cancer Center supports research aimed at "Targeting Ganglioside GD2 to Overcome Chemotherapy Resistance in Triple-Negative Breast Cancer". This 4-year grant, awarded on September 1, 2025, will fund advanced biomedical research to transform healthcare for military service members, veterans, and the public by...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...